CytoDyn Inc.: Form 10-Q for the period ended Feb 29, 2024
Filed with the SEC on Apr 15, 2024 and accepted by EDGAR at Apr 15, 2024, 21:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-02-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-12-01 to 2024-02-29 | $650.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-06-01 to 2024-02-29 | $3.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-12-01 to 2024-02-29 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-06-01 to 2024-02-29 | −$11.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-12-01 to 2024-02-29 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-06-01 to 2024-02-29 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-12-01 to 2024-02-29 | −$11.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-06-01 to 2024-02-29 | −$33.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-12-01 to 2024-02-29 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-06-01 to 2024-02-29 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-12-01 to 2024-02-29 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-06-01 to 2024-02-29 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-12-01 to 2024-02-29 | 982,209,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-06-01 to 2024-02-29 | 954,814,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-06-01 to 2024-02-29 | −$9.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-02-29 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-02-29 | $9.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-02-29 | $10.3m | us-gaap:Assets |
| Current liabilities | At period end2024-02-29 | $129.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-02-29 | $129.7m | us-gaap:Liabilities |
| Long-term debt | At period end2024-02-29 | $44.2m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-02-29 | −$119.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-005134. Last ingested by Listed: Oct 24, 2026, 14:53 ET. Listed shows no prices and gives no investment advice.